Reply to "Development of an Atherogenic Metabolic Risk Factor Profile Associated With the Use of Atypical Antipsychotics."

View This PDF

NB: This article is only available as a PDF.

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: We are grateful to have been given the opportunity to reply to the letter by Karagianis and Dunayevich. We by all means agree that a cross-sectional study has limitations in its design. Our study should be considered as a first attempt to document the metabolic risk profile of patients who had been exposed for the same period of time to 2 atypical antipsychotics: olanzapine and risperidone.​

J Clin Psychiatry 2005;66(1):138